Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Global health

Evidence still lacking for Ebola treatments, concludes European Medicines Agency

There is a lack of evidence for seven investigational drugs for treatment of Ebola virus, concludes European Medicines Agency (EMA)

Source: Greg E. Mathieson Sr. / Rex Features

There is a lack of evidence for seven investigational drugs for treatment of Ebola virus, concludes European Medicines Agency (EMA)

Lack of evidence for seven investigational drugs being developed for the treatment of Ebola virus disease means it is impossible to make any conclusions about their safety or efficacy, according to the findings of an interim review by the European Medicines Agency (EMA) published on 16 December 2014.

The amount of evidence available for the products is “highly variable” and for some there are no available data about their use in humans, the report by the EMA’s Committee for Medicinal Products for Human Use says.

Some of the available evidence relates to products that have been used in humans but for the treatment of other viruses, the report points out. It also says that the appropriate dosing of all the products reviewed is uncertain.

The seven products considered by the review, which is ongoing, are: BCX4430 (developed by Biocryst); brincidofovir (Chimerix); favipiravir (Fujifilm Corporation/Toyama);TKM-100802 (Tekmira); AVI-7537 (Sarepta); ZMapp (Leafbio Inc.); Anti-Ebola F(ab’)2 (Fab’entech).

The review does not include Ebola vaccines.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067446

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.